Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05290597 |
| Title | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Innovent Biologics (Suzhou) Co. Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Kate.Wilkinson1@health.nsw.gov.au | RECRUITING | Sydney | New South Wales | 2109 | Australia | Details |
| Westmead Hospital | RECRUITING | Sydney | New South Wales | 2145 | Australia | Details |
| Sydney Southwest Private Hospital | RECRUITING | Sydney | New South Wales | 2170 | Australia | Details |
| Cancer Care Wollongong | RECRUITING | Sydney | New South Wales | 2500 | Australia | Details |